



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Lalruatadika Varte, Drugs Inspector
Office of the Chief Medical Officer
Kolasib, Mizoram- 796082
2. Serial No. and date of Inspector's memorandum : 006/IPA-KLB/III-25 , 16-JUN-2025
3. Number of Sample : NIL
4. Date of receipt : 26-JUN-2025
5. Names of drugs purporting to be contained in the sample : Telmisartan Tablets IP 40 mg. (Savtel 40 Tablets)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0611	GUW/LS/2025-26/616	PT-40584	Feb-2024 Jan-2026	NA	Pharmaroots Healthcare, Khasra No. 411, Village Tipra, P.O. Barotiwala, Tehsil Baddi, Distt. Solan, H.P.

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 22-Jul-2025 To 21-Aug-2025

COMPOSITION : Each film coated tablet contains: Telmisartan IP 40 mg.

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Telmisartan.	NA
3	Average weight	0.3467 g	NA
4	Uniformity of weight	Complies.	+5 % of Average weight
5	Dissolution	Complies at S2 stage, Average Drug release 76.4% of claim. Out of 12 units no unit is found Q-15% i.e. 60% of claim.	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1	Telmisartan	41.84 mg/Tablet	40 mg/Tablet	104.6	90 % to 110 %	I.P. 2022
---	-------------	-----------------	-----------------	-------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 26-AUG-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-77

-----END OF REPORT-----

